Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/26/2020 10:29 PDT] Editas Medicine, Inc. (NASDAQ:EDIT), Up By 100.00% ($26.15) After BUYINS.NET SqueezeTrigger Report Released on Monday, April 20th 2020 at a Price of $26.150.
• [05/26/2020 10:29 PDT] Editas Medicine, Inc. (NASDAQ:EDIT), Up By 100.00% ($26.39) After BUYINS.NET SqueezeTrigger Report Released on Monday, April 27th 2020 at a Price of $26.390.
• [05/26/2020 10:29 PDT] Editas Medicine, Inc. (NASDAQ:EDIT), Up By 100.00% ($26.09) After BUYINS.NET SqueezeTrigger Report Released on Monday, May 11th 2020 at a Price of $26.090.
• [05/15/2020 07:40 PDT] EDIT Expected to Trade Down After Bearish Patterns Develop
• [05/14/2020 07:32 PDT] EDIT Expected to Trade Down After Bearish Patterns Develop
• [05/13/2020 08:16 PDT] EDIT SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/12/2020 07:52 PDT] EDIT, Expected to Trade Lower After Bearish Insider Trading
• [05/11/2020 12:42 PDT] EDIT SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [04/28/2020 07:24 PDT] EDIT Expected to Trade Up After Bullish Patterns Develop
• [04/27/2020 13:01 PDT] EDIT SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [04/21/2020 07:34 PDT] EDIT Expected to Trade Up After Bullish Patterns Develop
• [04/20/2020 13:20 PDT] EDIT SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.